ALNA stock $0.08 on 08 Jan 2026 NASDAQ: most active with 252,311,606 shares, check runway
We saw ALNA stock finish the market closed session at $0.075 on 08 Jan 2026 on the NASDAQ in the United States, trading 252,311,606 shares. The penny stock moved between $0.06 and $0.15 intraday, lifting the price 3.16% from the prior close. Volume and volatility drove the session, and investors should weigh liquidity and cash metrics before acting. This article gives a concise ALNA stock analysis, key ratios, Meyka AI grading, and a model forecast to frame risk and opportunity.
ALNA stock intraday performance and trading facts
ALNA stock opened at $0.06 and closed at $0.075 on 08 Jan 2026 on NASDAQ in USD. The day high was $0.1459 and the day low was $0.06, showing wide intraday swings. Volume was 252,311,606 shares, well above typical levels and consistent with a most active session.
High volume often indicates rapid positional changes by traders. For ALNA, a low share price and reported EPS of -0.64 drive outsized percent moves. The reported PE ratio is negative at -0.12, reflecting losses and no earnings base for traditional valuation.
ALNA stock financials and balance-sheet metrics
Allena Pharmaceuticals, Inc. (ALNA) is listed on the NASDAQ and operates in Healthcare, specifically Biotechnology. Key per-share metrics show cash per share $0.92, book value per share $0.58, and working capital around $17,327,000.00. Enterprise value is reported at -$29,461,000.00, reflecting small market cap reporting and cash holdings.
Profitability and cash flow are weak. Net income per share TTM is -1.03, operating cash flow per share TTM is -1.41, and free cash flow per share TTM is -1.43. The current ratio is 2.11, which supports short-term liquidity despite ongoing negative earnings.
ALNA stock technicals, volatility and Meyka AI grade
ALNA stock shows long-term declines: year change and multi-year losses exceed 80.00% to 99.25% in some time frames. Price averages are not available, which limits simple moving average signals. Traders should expect high volatility and wide bid-ask spreads at this price level.
Meyka AI rates ALNA with a score out of 100: 62.75 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational only and not financial advice.
ALNA stock valuation, sector context and risks
As a small biotech, Allena faces typical sector risks: trial outcomes, FDA timing, and funding needs. Revenue per share TTM is $0.00, and R&D-to-revenue ratios are not meaningful because revenue is nil. Price-to-book is low at 0.13, reflecting low market pricing relative to book value.
Key risks include dilution and development setbacks. The company’s interest coverage is negative at -63.40, which is common for early-stage biotechs but highlights limited operating earnings. Compare ALNA stock to the broader Healthcare sector performance when sizing a position.
ALNA stock outlook, catalysts and near-term drivers
Near-term catalysts for ALNA stock include clinical updates on ALLN-346, regulatory guidance, and financing announcements. Positive trial news could trigger sharp rallies because the float at penny prices amplifies moves. Conversely, missed milestones or equity raises would pressure the share price.
Investors should track cash runway and press releases. We note the last formal earnings announcement date in public records was 15 Aug 2022, and the company remains development-stage, emphasizing event-driven trading.
Final Thoughts
Key takeaways for ALNA stock: the market closed the session at $0.075 on 08 Jan 2026 with 252,311,606 shares traded, marking the name as one of the most active on NASDAQ that day. Financials show cash per share $0.92 and negative EPS -0.64, supporting a cautious view. Meyka AI’s grade of B (62.75) signals HOLD, based on sector and metric comparisons and limited growth data. Meyka AI’s forecast model projects a short-term base case target of $0.20, implying 166.67% upside from $0.075. This projection reflects event-driven upside if clinical progress resumes, but forecasts are model-based projections and not guarantees. Given the high intraday range, tight risk management and position sizing are essential. We recommend monitoring official company updates, trial milestones, and any financing news to reassess ALNA stock outlook and price targets in real time. Meyka AI is an AI-powered market analysis platform providing these data-driven views.
FAQs
What is the current price and volume for ALNA stock?
ALNA stock closed at $0.075 on 08 Jan 2026 on NASDAQ with 252,311,606 shares traded in the session. Intraday range was $0.06 to $0.1459.
What does the Meyka AI grade say about ALNA stock?
Meyka AI rates ALNA with a score out of 100: 62.75, Grade B, Suggestion HOLD. The grade factors S&P and sector comparisons, financial growth, key metrics, and analyst signals.
What headline risks should investors watch for ALNA stock?
Investors should watch clinical readouts for ALLN-346, regulatory updates, and any equity financing. Those events can move ALNA stock sharply given low per-share price and high volatility.
What is Meyka AI’s forecast for ALNA stock?
Meyka AI’s forecast model projects a base-case target of $0.20, implying 166.67% upside from $0.075. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
